ARYA Sciences Acquisition Corp IV (ARYD)
(Delayed Data from NSDQ)
$6.64 USD
0.00 (0.00%)
Updated Jul 31, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ARYD 6.64 0.00(0.00%)
Will ARYD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ARYD based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for ARYD
Adagio Medical Announces the Closing of the Business Combination with ARYA IV, Creating a Publicly Traded Company Focused on the Innovative Technologies for Treatment of Cardiac Arrhythmias
ARYA Sciences Acquisition IV Announces Merger with Adagio Medical
Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider